, 4-dihydroquinazolin-6-yl)-N 1 -(2,4-dichlorophenyl)thiourea (7f): According to the method B (r.t., 1 h), compound 7f was isolated as a colorless solid (446 mg, 89%), p.265

H. , 24 (s, 1H, DMSO-d 6 ) ? 10.28 (s, 1H, NH), 9.70 (s, 1H, NH), 8.32 (d, J = 2.4 Hz, 1H, H 5 ), vol.8, p.1

, 188-190?C; 1 H-NMR (DMSO-d 6 ) ? 10.29 (s, 1H, NH), N-(3-Cyclopropyl-4-oxo-3,4-dihydroquinazolin-6-yl)-N 1 -(pyridin-3-yl)thiourea (7g): According to the method A (40?C (µW), 1 h), compound 7g was isolated as a colorless solid (309 mg, 89%), mp, vol.10, p.707, 1257.

, 99 (s, 1H, NH), N-(3-Cyclopropyl-4-oxo-3,4-dihydroquinazolin-6-yl)-N 1 -(p-tolyl)thiourea (7h): According to the method B (r.t., 2 h), compound 7h was obtained as a colorless solid (386 mg, 89%), vol.9, p.1, 1037.

, 81 (s, 1H, NH), 8.27 (d, J = 1.8 Hz, 1H, H 5 ), N-(3-Cyclopropyl-4-oxo-3,4-dihydroquinazolin-6-yl)-N 1 -(4-methoxyphenyl)thiourea (7i): According to the method B (r.t., 2 h), compound 7i was isolated as a colorless solid (395 g, 87%), vol.9, p.1

, 4-dihydroquinazolin-6-yl)-N 1 -(4-methoxyphenyl)thiourea (7j): According to the method A (r.t., 10 min.), compound 7j was isolated as a grey solid (340 mg, 87%), mp, pp.210-212

H. , 0 Hz, 2H, ArH), 6.72 (d, J = 9.0 Hz, 2H, ArH), 2.89 (s, 6H, NCH 3 ), 3.33-3.21 (m, 1H, NCH), DMSO-d 6 ) ? 9.77 (s, 1H, NH), 9.70 (s, 1H, NH), 8.27 (d, J = 2.4 Hz, 1H, H 5 ), 8.20 (s, 1H, H 2 ), 7.93 (dd, J = 8.7, 2.4 Hz, 1H, H 7 ), 7.59 (d, J = 8.7 Hz, 1H, H 8 ), 7.22 (d, J = 9

, 4-dihydroquinazolin-6-yl)-N 1 -(2,4-dimethoxyphenyl)thiourea (7k): According to the method A (r.t., 30 min.), product 7k was isolated as a black solid (396 mg, 97%), mp, pp.166-168

H. , mmol) and bromine (19.0 µL, 0.37 mmol, 1.0 equiv.), 2 h at room temperature. After purification, 8g was isolated as a colorless solid (100 mg, 80%), mp > 265?C; 1 H-NMR (DMSO-d 6 ) ? 10, 7.95 (dd, J = 8.7, 2.4 Hz, 1H, H 7 ), 7.60 (d, J = 8.7 Hz, 1H, H 8 ), 7.47 (d, J = 8.4 Hz, 1H, H 6 1 ), 6.64 (d, J = 2.7 Hz, 1H, H 3 1 ), 6.53 (dd, J = 8.4, 2.7 Hz, 1H, H 5 1 ), vol.3

, after 1 h at room temperature. After purification, 10a was isolated as a colorless solid (37 mg, 30%), mp. 258-260?C; 1 H-NMR (DMSO-d 6 ) ? 10.93 (s, 1H, NH), 8.72 (d, J = 2.3 Hz, 1H, H 5 ), mmol) in presence of bromine, vol.9, 1490.

, 35 (s, 1H, H 2 ), 8.07 (dd, J = 2.5, 8.8 Hz, 1H, mmol) and bromine (16.4 µL, 0.32 mmol, 1.0 equiv.), 30 min at room temperature. After purification, 10l was isolated as a colorless solid (113 mg, 90%), mp. 200?C; 1 H-NMR (DMSO-d 6 ) ? 10.73 (s, 1H, NH), 8.71 (d, J = 2.5 Hz, 1H, H 5 ), vol.8, p.625, 1219.

, 100 mg, 0.31 mmol, 1.0 equiv.) in DME (3 mL) was added the appropriate amine (0.33 mmol, 1.05 equiv.) at room temperature for 30 min. to 12 h. After completion, copper(I) iodide (5.7 mg, 0.03 mmol, 10 mol %) and cesium carbonate (208 mg, 0.64 mmol, 2.0 equiv.) were added and the resulting suspension was heated under microwave at 80?C for 1 h. The resulting mixture was adsorbed on Celite ® and purified by flash chromatography using ethyl acetate/methylene chloride (0/100 to 50/50, v/v) as eluent to furnish the expected fused 2-arylaminothiazoloquinazolinones 8a; c; h-n and 14a

, 204-206?C; 1 H-NMR (DMSO-d 6 ) ? 10.69 (s, 1H, NH), 8.30 (s, 1H, thiourea intermediate was obtained from 13 and aniline (30.7 mg) after 12 h at room temperature. After purification, 8a was isolated as a colorless solid (82.9 mg, 80%), mp, vol.696, p.1

, 8H)-one (8c): According to the general procedure, thiourea intermediate was obtained from 13 and 4-fluoroaniline (56.8 mg) after 2 h at room temperature. After purification

. Mhz, 69 (s, 1H, NH), 8.29 (s, 1H, 8.05 (d, J = 8.7 Hz, 1H, H 4 ), 7.88-7.86 (m, 1H, Molecules, vol.10, p.27, 2016.

. Ph, 7.66 (d, J = 8.7 Hz, 1H, H 5 ), 7.24 (m, 2H, Ph)
URL : https://hal.archives-ouvertes.fr/in2p3-01112063

, According to the general procedure, thiourea intermediate was obtained from 13 and p-toluidine (35.4 mg,) after 2 h at room temperature. After purification, -Cyclopropyl-2-(p-tolylamino)thiazolo[5,4-f]quinazolin-9(8H)-one (8h)

H. , DMSO-d 6 ) ? 10.56 (s, 1H, NH), 8.28 (s, 1H, H 7 ), 8.02 (d, J = 8.7 Hz, 1H, H 4 ), 7.71 (d, J = 8.1 Hz, 2H, Ph), 7.63 (d, J = 8.7 Hz, 1H, H 5 ), 7.20 (d, J = 8.1 Hz, vol.2, 1140.

, 8H)-one (8i): According to the general procedure, thiourea intermediate was obtained from 13 and p-anisidine (40.6 mg) after 2 h at room temperature. After purification

H. , 7.78 (d, J = 8.7 Hz, 1H, H 4 ), 7.72 (d, J = 9.0 Hz, 2H, Ph), 7.62 (d, J = 8.7 Hz, 1H, H 5 ), 6.98 (d, J = 9.0 Hz, vol.2, p.826, 1029.

, mg) after 1 h at room temperature. After purification, 8j was isolated as a pale yellow solid (101.7 mg, 87%), mp > 265?C; 1 H-NMR (DMSO-d 6 ) ? 10.27 (s, 1H, NH), 8.24 (s, 1H, H 7 ), 7.94 (d, J = 8.7 Hz, 1H, H 4 ), 7.61-7.56 (m, 3H, Ph + H 5 ), 7.78 (d, J = 9.1 Hz, vol.1, 1244.

, 5 mg) after 30 min. at room temperature. After purification, 8k was isolated as a brown solid (105.1 mg, 86%), mp. 240-242?C; 1 H-NMR (DMSO-d 6 ) ? 9, vol.2, p.822, 1023.

, According to the general procedure, thiourea intermediate was obtained from 13 and 4-aminoveratrole (50.5 mg) after 30 min. at room temperature. After purification, 8l was isolated as a colorless solid (110 mg, 90%), mp > 265?C; 1 H-NMR (DMSO-d 6 ) ? 10.47 (s, 1H, NH), vol.8

C. , , vol.3201, p.1, 1025.

, 2-(Benzylamino)-8-cyclopropylthiazolo[5,4-f]quinazolin-9(8H)-one (14a): According to the general procedure, thiourea intermediate was obtained from 13 and benzylamine (35.4 mg) after 30 min, thiourea intermediate was obtained from 13 and 4-aminobenzenesulfonamide (56.8 mg) after 12 h at room temperature. After purification, 8l was isolated as a beige solid (128.1 mg, 77%), mp > 265?C; 1 H-NMR (DMSO-d 6 ) ? 11.10 (s, 1H, NH), 8.30 (s, 1H, H 7 ), 8.10 (d, J = 8.6 Hz, 1H, H 4 ), 8.00 (d, J = 8.8, 2H, Ph), 7.83 (d, J = 8.8 Hz, Ph), vol.3296, p.832, 1153.

N. and N. -dimethylethylenediamine, 1 mg) after 30 min. at room temperature. After purification, 14b was isolated as a colorless solid (98.0 mg, 96%), mp. 210-212?C; 1 H-NMR (DMSO-d 6 /CDCl 3 ) ? 8.12 (s, 1H, vol.29

, According to the general procedure, thiourea intermediate was obtained from 13 and 2-piperiridinylethylamine (43.0 mg) after 30 min. at room temperature. After purification, 14c was isolated as a colorless solid (104 mg, 91%), mp. 218-220?C; 1 H-NMR (DMSO-d 6 ) ? 8

C. , , vol.833, p.1, 1297.

, According to the general procedure, thiourea intermediate was obtained from 13 and 2-morpholinoethylamine (43.0 mg) after 30 min. at room temperature. After purification, 14d was isolated as a colorless solid (102 mg, 89%), mp. 222-224?C; 1 H-NMR (DMSO-d 6 ) ? 8.27 (s, 1H, 8.25 (br, 1H, NH), 7.89 (d, J = 8.4 Hz, 1H, H 4 ), vol.7, p.61

, 8H)-one (14e): According to the general procedure, thiourea intermediate was obtained from 13 and piperidine (26.3 mg) after 30 min, pp.244-246

H. , CDCl 3 ) ? 8.05 (s, 1H, H 7 ), 7.88 (d, J = 8.4 Hz, 1H, H 4 ), vol.7, p.27

, 1280 found 327.1283. 8-Cyclopropyl-2-(piperidin-1-yl)thiazolo[5,4-f]quinazolin-9(8H)-one (14f): According to the general procedure, thiourea intermediate was obtained from 13 and morpholine (28.7 mg) after 30 min. at room temperature. After purification, 14f was isolated as a colorless solid (93.6 mg, 92%), mp. 230-232?C; 1 H-NMR (DMSO-d 6 ) ? 8.26 (s, 1H, HRMS calcd for C 17 H 19 N 4 OS, vol.824, p.1, 1112.

, General Procedure for the Synthesis of N-Alkyl-8-cyclopropyl-9-oxo-8,9-dihydrothiazolo[5,4-f ] quinazoline-2-carboximidamides 17a-f from 16

, In a sealed tube, a solution of carbonitrile derivative 16 (75 mg, 0.28 mmol) and the appropriate amine (2.8 mmol, 10 equiv.) in THF (1 mL) was heated under microwaves at 100?C for 45 min under argon atmosphere. The solvent was removed under vacuum and the crude residue was adsorbed on Celite ®

, quinazoline-2-carboximidamide (17a): beige powder (105 mg, 93%), mp. 148-150?C; 1 H-NMR (DMSO-d 6 ) ? 8.48 (s, 1H, H 7 ), 8.43 (d, J = 9.0 Hz, 1H, H 4 ), 7.84 (d, J = 9.0 Hz, 1H, H 5 ), 7.49-7.23 (m, 5H, Ph), 6.99, vol.3328, p.826, 1091.

, quinazoline-2-carboximidamide (17b): colorless solid (99 mg, 99%), mp. 168-170?C; 1 H-NMR (DMSO-d 6 ) ? 8.46 (s, 1H, vol.8

, -morpholinoethyl)-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carboximidamide (17c): colorless solid (63 mg, 57%), mp, pp.154-156

1. Hz, m, 4H, OCH 2 ), 3.48 (t, J = 6.0 Hz, H1 1 ), 3.37-3.32 (m, 1H, NCH), 2.76 (t, J = 6.0 Hz, H2 1 ), 2.63-2.60 (m, 4H, NCH 2 ), 1.30-1.23 (m, 2H, CH, vol.3374, p.1, 1110.

1. Hz, (m, 2H, H1 1 ), 3.37-3.33 (m, 1H, NCH), 2.70-2.66 (m, 1H, H2 1 ), 2.52-2.50 (m, 4H, NCH), 1.65-1.59 (m, 4H, CH), 1.49-1.30 (m, 4H, CH), 1.30-1, vol.3325, p.1, 1040.

, mg, 54%), mp. 184-186?C ; 1 H-NMR (DMSO-d 6 ) ? 8.48 (s, 1H, H 7 ), vol.8, p.1, 1109.

, HRMS calcd for C 17 H 25 N 5 O 2 S

, 204-206?C ; 1 H-NMR (DMSO-d 6 ) ? 8.50 (s, 1H, mg, 59%), mp, vol.8

N. and N. , N 1 -tetraacetic acid (EGTA), 1 mM dithiothreitol (DTT), 25 mM Tris-HCl pH 7.5, 50 µg heparin/mL. Buffer B: ?-Glycerophosphate (60 mM), 30 mM p-nitrophenylphosphate, Buffer A: MgCl 2 (10 mM), 1 mM ethylene glycol-bis, vol.25

, Kinase Preparations and Assays Kinase activities were assayed in triplicates in buffer A or B, for 30 min. at 30?C, at a final adenosine triphosphate (ATP) concentration of 15 µM. Blank values were substracted and activities expressed in % of the maximal activity, i.e., in the absence of inhibitors. Controls were performed with appropriate dilutions of dimethylsulfoxide (DMSO). IC 50 values were calculated from dose-response curves established by Sigma-Plots. The GSK-3, CK1, DYRK1A and CLK1 peptide substrates were obtained from Proteogenix

, Its kinase activity was assayed in buffer A, with 1 mg of histone H1/mL, in the presence of 15 µM, CDK5/p25. (Human, recombinant) was prepared as previously described, vol.45

, Ci/mmol; 10 mCi/mL) in a final volume of 30 µL. After 30 min incubation at 30?C, 25 µL aliquots of supernatant were spotted onto sheets of Whatman P81 phosphocellulose paper, and 20 s later, the filters were washed eight times (for at least 5 min each time) in a solution of 10 mL phosphoric acid/L of water. The wet filters were counted in the presence of 1 mL ACS (Amersham) scintillation fluid. GSK-3?/?. (Porcine brain, native) was assayed, as described for CDK5/p25 but in buffer A and using a GSK-3 specific substrate, vol.46

/. Ck1?, Porcine brain, native) was assayed as described for CDK5/p25 but using the CK1-specific peptide substrate RRKHAAIGpSAYSITA, vol.47

. Dyrk1a, GST) fusion protein) was purified by affinity chromatography on glutathione-agarose and assayed, as described for CDK5/p25 using Woodtide (KKISGRLSPIMTEQ) (1.5 µg/assay) as a substrate. CLK1. (Human, recombinant, expressed in E. coli as GST fusion protein) was assayed in buffer A (+0.15 mg BSA/mL) with RS

G. Wells, T. D. Bradshaw, P. Diana, A. Seaton, D. Shi et al., 14 and 17) has been prepared, using microwave-assisted technology. An efficient multistep synthesis of 6-amino-3-cyclopropylquinazolin-4(3H)-one (3) was developed and optimized to the multigram scale, affording the synthesis of large quantities of a versatile and efficient precursor for the various target molecules in this study. The synthetic routes to these variously 8-aminoaryl thiazolo[5,4-f ]quinazolin-9(8H)-ones, incited us to re-explore some aspects of the Hügershoff reaction involving a first bromination on thiocarbonyl group of a thiourea, followed by intramolecular References 1, Conclusions A library of thirty eight novel thiazolo, vol.10, pp.513-515, 2000.

T. D. Bradshaw, S. Wrigley, D. Shi, R. J. Schultz, K. D. Paull et al., 2-(4-Aminophenyl)benzothiazoles: Novel agents with selective profiles of in vitro anti-tumour activity, Br. J. Cancer, vol.77, pp.745-752, 1998.

T. F. Molinski, Marine pyridoacridine alkaloids: structure, synthesis, and biological chemistry, Chem. Rev, vol.93, pp.1825-1838, 1993.

G. P. Gunawardana, S. Kohmoto, S. P. Gunasekara, O. J. Mcconnel, and F. E. Koehn, Dercitine, a new biologically active acridine alkaloid from a deep water marine sponge, Dercitus sp, J. Am. Chem. Soc, vol.110, pp.4856-4858, 1988.

G. P. Gunawardana, S. Kohmoto, and N. Burres, New cytotoxic acridine alkaloids from two deep water marine sponges of the family Pachastrellidae, Tetrahedron Lett, vol.30, pp.4359-4362, 1989.

V. Bénéteau and T. Besson, Synthesis of novel pentacyclic pyrrolothiazolobenzoquinolinones, analogs of natural marine alkaloids, Tetrahedron Lett, vol.42, pp.2673-2676, 2001.

C. Lamazzi, H. Chabane, V. Thiéry, A. Pierre, S. Léonce et al., Synthesis and cytotoxic evaluation of novel thiazolocarbazoles, J. Enzyme Inhib. Med. Chem, vol.17, pp.397-401, 2002.

S. Frère, V. Thiéry, C. Bailly, and T. Besson, Novel 6-substituted benzothiazol-2-yl indolo[1,2-c]quinazolines and benzimidazo[1,2-c]quinazolines, Tetrahedron, vol.59, pp.773-779, 2003.

H. Chabane, A. Pierre, S. Léonce, B. Pfeiffer, P. Renard et al., Synthesis and cytotoxic activity of thiazolofluorenone derivatives, J. Enzyme Inhib. Med. Chem, vol.19, pp.567-575, 2004.

A. Testard, L. Picot, I. Fruitier-arnaudin, J. M. Piot, H. Chabane et al., Microwave-assisted synthesis of novel thiazolocarbazoles and evaluation as potential anticancer agents. Part III, J. Enzyme Inhib. Med. Chem, vol.19, pp.467-473, 2004.
URL : https://hal.archives-ouvertes.fr/hal-01967795

C. Logé, A. Testard, V. Thiéry, O. Lozach, M. Blairvacq et al., Novel 9-oxo-thiazolo[5,4-f ]quinazoline-2-carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK1)/glycogen synthase kinase-3 (GSK-3) inhibitors: Synthesis, biological evaluation and molecular modeling studies, Eur. J. Med. Chem, vol.43, pp.1469-1477, 2008.

A. Testard, C. Logé, B. Léger, J. Robert, O. Lozach et al., Thiazolo[5,4-f ]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3, Bioorg. Med. Chem. Lett, vol.16, pp.3419-3423, 2006.

Y. Loidreau, E. Deau, P. Marchand, M. Nourrisson, C. Logé et al., ] pyrimidin-4-amines as multitarget Ser/Thr kinases inhibitors, Eur. J. Med. Chem, vol.92, pp.124-134, 2015.

Y. Loidreau, P. Marchand, C. Dubouilh-benard, M. Nourrisson, M. Duflos et al., ]pyrimidin-4-amine analogues as dual inhibitors of CLK1 and DYRK1A kinases, Eur. J. Med. Chem, vol.59, pp.283-295, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00997416

Y. Loidreau, P. Marchand, C. Dubouilh-benard, M. Nourrisson, M. Duflos et al., Synthesis and biological evaluation of N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amines and their pyrido and pyrazino analogues as Ser/Thr kinase inhibitors, Eur. J. Med. Chem, vol.58, pp.171-183, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00997084

A. Foucourt, D. Hédou, C. Dubouilh-benard, L. Désiré, A. Casagrande et al., Design and synthesis of thiazolo[5,4-f ]quinazolines as DYRK1A inhibitors, Part I, Molecules, vol.19, pp.15546-15571, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01109410

A. Foucourt, D. Hédou, C. Dubouilh-benard, L. Désiré, A. Casagrande et al., Design and synthesis of thiazolo[5,4-f ]quinazolines as DYRK1A inhibitors, Part II, Molecules, vol.19, pp.15411-15439, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01135223

B. Leblond, A. Casagrande, L. Désiré, A. Foucourt, and T. Besson, DYRK1 inhibitors and uses thereof WO 2013026806, Chem. Abstr, vol.158, p.390018, 2013.

R. Appel, H. Janssen, M. Siray, and F. Knoch, Synthese und Reaktionen des 4,5-Dichlor-1,2,3-dithiazolium-chlorids, Chem. Ber, vol.118, pp.1632-1643, 1985.

Y. J. Esvan, W. Zeinyeh, T. Boibessot, L. Nauton, V. Théry et al., Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure, Eur. J. Med. Chem, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01308803

C. Schmitt, P. Miralinaghi, M. Mariano, R. W. Hartmann, and M. Engel, Hydroxybenzothiophene ketones are efficient pre-mRNA splicing modulators due to dual inhibition of Dyrk1A and Clk1/4, ACS Med. Chem. Lett, vol.5, pp.963-967, 2014.

O. Dehbi, A. Tikad, S. Bourg, P. Bonnet, O. Lozach et al., Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A Inhibitors, Eur. J. Med. Chem, vol.80, pp.352-363, 2014.

M. Bajda, N. Guzior, M. Ignasik, and B. Malawska, Multi-target-directed ligands in Alzheimer's disease treatment, Curr. Med. Chem, vol.18, pp.4949-4975, 2011.

A. Cavalli, M. L. Bolognesi, A. Minarini, M. Rosini, V. Tumiatti et al., Multi-target-directed ligands to combat neurodegenerative diseases, J. Med. Chem, vol.51, pp.347-372, 2008.

D. Hédou, J. Godeau, N. Loaëc, L. Meijer, C. Fruit et al., Synthesis of Thiazolo[5,4-f ]quinazolin-9(8H)-ones as Multi-Target Directed Ligands of Ser/Thr Kinases, Molecules, vol.21, 2016.

F. R. Alexandre, L. Domon, S. Frère, A. Testard, V. Thiéry et al., Microwaves in drug discovery and multi-step synthesis, Mol. Divers, vol.7, pp.273-280, 2003.

F. R. Alexandre, A. Berecibar, R. Wrigglesworth, and T. Besson, Efficient synthesis of thiazoloquinazolinone derivatives, Tetrahedron Lett, vol.44, pp.4455-4458, 2003.

T. Besson, J. Guillard, and C. W. Rees, Multistep synthesis of thiazoloquinazolines under microwave irradiation in solution, Tetrahedron Lett, vol.41, pp.1027-1030, 2000.

A. Hugershoff, Einwirkung von Brom auf aromatische Thioharnstoffe, Ber. Dtsch. Chem. Ges, vol.36, pp.3121-3134, 1903.

A. Hugershoff, Einwirkung von Halogenen auf Thioharnstoffe, Ber. Dtsch. Chem. Ges, vol.34, pp.3130-3135, 1901.

D. A. Jordan, C. Luo, and A. Reitz, Efficient conversion of substituted aryl thioureas to 2-aminobenzothiazoles using benzyltrimethylammonium bromide, J. Org. Chem, vol.68, pp.8693-8696, 2003.

K. Inamoto, C. Hasegawa, J. Kawasaki, K. Hiroya, and T. Doi, Use of molecular oxygen as a reoxidant in the synthesis of 2-substituted benzothiazoles via palladium-catalyzed C-H functionalization/intramolecular C-S bond formation, Adv. Synth. Catal, vol.352, pp.2643-2655, 2010.

K. Inamoto, C. Hasegawa, K. Hiroya, and T. Doi, Palladium-catalyzed synthesis of 2-substituted Benzothiazoles via C-H functionalization/intramolecular C-S bond formation process, Org. Lett, vol.10, pp.5147-5150, 2008.

L. L. Joyce and R. A. Batey, Heterocycle formation via palladium-catalyzed intramolecular oxidative C-H bond functionalization: An Efficient Strategy for the Synthesis of 2-aminobenzothiazoles, Org. Lett, vol.11, pp.2792-2795, 2009.

G. Evindar and R. A. Batey, Parallel Synthesis of a library of benzoxazoles and Benzothiazoles using ligand-accelerated copper-catalyzed cyclizations of ortho-halobenzanilides, J. Org. Chem, vol.71, pp.1802-1808, 2006.

L. L. Joyce, G. Evindar, and R. A. Batey, Copper-and palladium-catalyzed intramolecular C-S bond formation: A convenient synthesis of 2-aminobenzothiazoles, Chem. Commun, pp.446-447, 2004.

D. Hédou, M. Harari, J. Godeau, C. Dubouilh-benard, C. Fruit et al., Synthesis of polyfunctionalized benzo[d]thiazoles as novel anthranilic acid derivatives, Tetrahedron Lett, vol.56, pp.4088-4092, 2015.

D. Hédou, E. Deau, M. Harari, M. Sanselme, C. Fruit et al., Rational multistep synthesis of a novel, Tetrahedron, vol.70, pp.5541-5549, 2014.

D. Hédou, R. Guillon, C. Lecointe, C. Logé, E. Chosson et al., Novel synthesis of angular thiazolo, Tetrahedron, vol.69, pp.3182-3191, 2013.

S. S. Michaelidou and P. A. Koutentis, The synthesis of 2-cyano-cyanothioformanilides from 2-(4-chloro-5H-1,2,3-dithiazol-5-ylideneamino)benzonitriles using DBU, Synthesis, pp.4167-4174, 2009.

T. Besson, J. Guillard, C. W. Rees, and V. Thiéry, New syntheses of aryl isothiocyanates, J. Chem. Soc. Perkin Trans, vol.1, pp.889-892, 1998.

J. G. Topliss, Utilization of operational schemes for analog synthesis in drug design, J. Med. Chem, vol.15, pp.1006-1011, 1972.

F. Giraud, G. Alves, E. Debiton, L. Nauton, V. Thery et al., Synthesis, protein kinase inhibitory potencies, and in vitro antiproliferative activities of meridianin derivatives, J. Med. Chem, vol.54, pp.4474-4489, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00609975

S. Bach, M. Knockaert, J. Reinhardt, O. Lozach, S. Schmitt et al., Roscovitine targets, protein kinases and pyridoxal kinase, J. Biol. Chem, vol.280, pp.31208-31219, 2005.
URL : https://hal.archives-ouvertes.fr/hal-00018751

S. Leclerc, M. Garnier, R. Hoessel, D. Marko, J. A. Bidd et al., Indirubins inhibit glycogen synthase kinase-3? and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's Disease: A property common to most cyclin-dependent kinase inhibitors?, J. Biol. Chem, vol.276, pp.251-260, 2001.

A. Primot, B. Baratte, M. Gompel, A. Borgne, S. Liabeuf et al., Purification of GSK-3 by affinity chromatography on immobilized axin, Protein Expr. Purif, vol.20, pp.394-404, 2000.

J. Reinhardt, Y. Ferandin, and L. Meijer, Purification of CK1 by affinity chromatography on immobilised axin, Protein Expr. Purif, vol.54, pp.101-109, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00169405

P. Jain, C. Karthikeyan, N. S. Moorthy, D. K. Waiker, A. K. Jain et al., Human CDC2-like kinase 1 (CLK1): A novel target for Alzheimer's disease, Curr. Drug Targets, vol.15, pp.539-550, 2014.

K. Patel, M. Gadewar, R. Tripathi, S. K. Prasad, and D. K. Patel, A review on medicinal importance, pharmacological activity and bioanalytical aspects of beta-carboline alkaloid, Harmine". Asian Pac. J. Trop. Biomed, vol.2, pp.660-664, 2012.

, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license